Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(60.0%)
Phase 3
2(40.0%)
5Total
Phase 4(3)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01385319Phase 3Unknown

Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study

Role: lead

NCT00611286Phase 4Completed

Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention

Role: lead

NCT01462188Phase 4Unknown

Optimizing Infarct Size by Transforming Emergent Stenting Into an Elective Procedure Study

Role: lead

NCT00229515Phase 4Unknown

Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI

Role: lead

NCT00597324Phase 3Completed

Predictive Value of Allen's Test Result in Elective Patients Undergoing Coronary Catheterization Through Radial Approach

Role: lead

All 5 trials loaded